Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Share-based Compensation (2017 - 2025)

Crinetics Pharmaceuticals has reported Share-based Compensation over the past 9 years, most recently at $21.7 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 15.26% year-over-year to $21.7 million; the TTM value through Dec 2025 reached $91.0 million, up 31.18%, while the annual FY2025 figure was $91.0 million, 31.18% up from the prior year.
  • Share-based Compensation for Q4 2025 was $21.7 million at Crinetics Pharmaceuticals, down from $22.7 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $26.1 million in Q2 2025 and troughed at $3.4 million in Q1 2021.
  • A 5-year average of $12.3 million and a median of $10.6 million in 2023 define the central range for Share-based Compensation.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 86.14% in 2024 and later rose 15.26% in 2025.
  • Year by year, Share-based Compensation stood at $5.2 million in 2021, then surged by 54.09% to $7.9 million in 2022, then skyrocketed by 46.16% to $11.6 million in 2023, then soared by 62.22% to $18.8 million in 2024, then grew by 15.26% to $21.7 million in 2025.
  • Business Quant data shows Share-based Compensation for CRNX at $21.7 million in Q4 2025, $22.7 million in Q3 2025, and $26.1 million in Q2 2025.